Stockreport

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Acurx Pharmaceuticals, Inc.  (ACXP) 
PDF New analyses extend data on beneficial effects of ibezapolstat on the gut microbiomeConfirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and [Read more]